Table SI. Dose-response relationship between the number of metastatic sites and overall survival.

Comparison	HR (95% CI)	P-value
2 vs. 1 site	1.52 (0.73–3.15)	0.259
3 vs. 1 site	3.53 (1.60–7.79)	0.002
≥4 vs. 1 site	5.68 (2.28–14.17)	<0.001
Per additional site (continuous)	1.65 (1.32–2.07)	<0.001

Table SII. Association of inflammatory and nutritional indices with the disease-free interval (n=61).

Index	Spearman ρ	P-value	Median DFS, unfavorable vs. favorable, months	P-value
PNI	+0.095	0.474	32.5 vs. 23.2	0.471
PLR	−0.106	0.415	28.4 vs. 24.4	0.919
SII	+0.001	0.991	26.2 vs. 24.9	0.967
SIRI	+0.067	0.605	24.0 vs. 26.3	0.623
mGPS	NA	NA	26.1 vs. 24.9	0.740
CRP	+0.081	0.580	NA	NA
NLR	−0.101	0.440	NA	NA
ALBI	+0.119	0.410	NA	NA
HALP	+0.109	0.413	NA	NA

Dichotomized comparisons use the cut-offs in Table V and were tested by the Mann-Whitney U test. PNI, prognostic nutritional index; PLR, platelet-to-lymphocyte ratio; SII, systemic immune-inflammation index; SIRI, systemic inflammation response index; mGPS, modified Glasgow Prognostic Score; CRP, C-reactive protein; NLR, neutrophil-to-lymphocyte ratio; ALBI, albumin-bilirubin; HALP, hemoglobin-albumin-lymphocyte-platelet index; DFS, disease-free survival; NA, not applicable.

Table SIII. Sensitivity analyses: Hazard ratio for ≥3 metastatic sites after separate adjustment.

Adjusted for	n	HR (95% CI)	P-value
De novo vs metachronous	104	3.04 (1.77–5.23)	<0.001
Age	104	3.12 (1.81–5.37)	<0.001
HER2-low status	104	3.18 (1.84–5.52)	<0.001
Primary surgery	104	2.93 (1.70–5.03)	<0.001
Treatment era	104	2.88 (1.67–4.96)	<0.001
Center	104	3.46 (1.99–6.03)	<0.001
mGPS	87	3.23 (1.71–6.09)	<0.001
PD-L1 status	56	3.39 (1.42–8.08)	0.006
Disease-free interval	61	3.71 (1.83–7.54)	<0.001
Germline BRCA status	39	2.86 (0.99–8.30)	0.053

HR, hazard ratio; CI, confidence interval; HER2, human epidermal growth factor receptor 2; mGPS, modified Glasgow Prognostic Score; PD-L1, programmed death-ligand 1; BRCA, breast cancer gene.